Lowering IL-6 or hsCRP-measured systemic inflammation reduces cardiovascular events regardless of the anti-inflammatory agent used
Reassessed: still Doubtful
verdict confidence 0.70 → 0.75 · credence 0.15
Assessed doubtful no decomposition
This first pass ran on a tight budget, so the claim was left atomic and assessed as doubtful (credence 0.15) on the mixed trial record: CANTOS and the chronic colchicine trials were positive, while CLEAR SYNERGY and ZEUS were null despite lowering the biomarkers. The ZEUS figures were not verified in this pass. A future pass should verify ZEUS, record instances, and consider arguments grouped by mechanism.
Assessed Doubtful
verdict confidence 0.70 · credence 0.15
The claim is that lowering systemic inflammation, as measured by IL-6 or hsCRP, reduces cardiovascular events whatever drug does the lowering. Read this way, the biomarker is a valid surrogate across mechanisms. The trial record weighs against that. Some agents that lower these markers do reduce events. Canakinumab, which blocks IL-1β, cut major adverse cardiovascular events by about 15% in CANTOS, and the benefit was concentrated in patients whose hsCRP or IL-6 fell. Low-dose colchicine reduced events in COLCOT and LoDoCo2. Other evidence breaks the link between the marker and the outcome. Colchicine lowered CRP but did not reduce events after myocardial infarction in CLEAR SYNERGY (OASIS 9). The IL-6 ligand inhibitor ziltivekimab has been reported to lower IL-6 and hsCRP sharply without changing event rates in ZEUS. Several other anti-inflammatory programmes, including darapladib, varespladib and losmapimod, also failed, although they did less to lower these markers, so they test the claim less directly. Taken together, the benefit looks tied to particular pathways (IL-1β and NLRP3) or particular clinical settings, not to lowering the biomarker as such. A universal "regardless of agent" claim is undercut by any well-powered trial in which the marker falls and events do not. The ongoing ziltivekimab outcome trials (ARTEMIS, HERMES) and fuller ZEUS publications would sharpen the judgment.
Claim entered the graph